HOME >> BIOLOGY >> NEWS
Drug-naive schizophrenia: The dopamine connection

Since the introduction of chlorpromazine in psychiatry in 1952, all antipsychotic drugs with proven efficacy have been dopamine (DA) D2 receptor antagonists. It has been suggested that positive schizophrenic symptoms (such as hallucinations) are associated with increased subcortical DA neurotransmission, and negative and cognitive symptoms with impaired mesocortical DA function. Studies on striatal D2 receptor densities in drug-naive schizophrenic patients have indicated that deviation in D2 density is larger among patients vs. controls, and although some patients have markedly elevated D2 levels, the D2 densities do not differ substantially at group level. Although DA neurotransmission in basal ganglia may be more important for motor functions rather than for emotions and behavioral symptoms, D2 binding studies have previously concentrated in the striatum, because there have been no suitable in vivo -ligands available for measuring extrastriatal D2 receptor binding. The aim of this study was to test the hypothesis that extrastriatal D2/3 density in temporal and cingulate cortex is lower among drug naive schizophrenic patients when compared with matched controls.

The results indicate that in drug-naive schizophrenic patients the extrastriatal dopamine D2/3 receptor density is markedly decreased. The authors also observed negative correlations between D2/3 receptor density and age among controls, and between D2/3 density and negative and general psychopathological symptom scores among patients. These results support the previous hypothesis on dysfunction of mesocortical dopamine function behind the cognitive and negative symptoms in schizophrenia.


'"/>

Contact: Aimee Midei
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
12-May-2003


Page: 1

Related biology news :

1. Cognitive therapy for schizophrenia: Hope for those whom drugs havent helped
2. Vollum scientists find new form of dopamine transmission
3. How amphetamine affects the dopamine transporter
4. The dopamine receptor D1 gene and ADHD: A piece of the genetic puzzle?
5. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
6. Molecule awakens and maintains neural connections
7. The Mediterranean connection: ecological effects of El Nio in the Northern hemisphere
8. OHSU researchers discover possible connection between infant hormone exposure, obesity
9. Gene essential for development of normal brain connections resulting from sensory input discovered
10. K-State professor examines connections between food, culture and psychology in new book
11. New study clarifies connection of brain and heart failure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
(Date:3/22/2017)... BEACH, Florida , March 22, 2017 ... ... for various cancer conditions are being pressured as of late ... therapy for cancer pain management has a dramatic impact on ... up research and development activities for identifying new forms of ...
Breaking Biology Technology:
Cached News: